15 September 2021
EFPIA Japan

EFPIA Japan Publishes "Communication Guidance for Vaccination"
to Facilitate Communications between Healthcare Professionals
and Vaccine RecipientsTOKYO – 15 September 2021 – EFPIA Japan today published "Communication Guidance for
Vaccination" on its website (efpia.jp/english-vaccines_work/).
The so-called vaccine gap between Japan and global standards, which was a major issue invaccination in Japan, has been significantly improved in the last 10 years largely due to theefforts of the government and pharmaceutical industry. Amid the ongoing COVID-19 pandemic,
the immunization of COVID-19 vaccines using new modalities is being rolled out at a full scale inthe country. Because of the limited experience with these vaccines and the high infectivity of thevirus, many people are interested in the efficacy and safety of the vaccines, and are receiving thevaccinations after accessing and understanding various information about the COVID-19vaccines.
EFPIA Japan promotes building an environment where all generations, from infants to the elderly,
are engaged in the prevention of infectious diseases (Life Course Immunization) in order toprotect the health of the people and medical front from not only COVID-19 infections but also
other infectious diseases. To create an environment where people can receive vaccinations withappropriate understanding of the significance of vaccinations, two-way communication between
physicians and vaccine recipients is very important. To this end, EFPIA Japan has developed anunprecedented "Communication Guidance for Vaccination" for healthcare professionals with thecooperation of communication experts as well as physicians.

“Communication Guidance for Vaccination” consists of two parts(Part 1) Dialogue examples when vaccination is given in doctor’s office(Part 2) Guidance commentaries on verbal and non-verbal communication

Link to the Guidance: http://www.efpia.jp/link/Vaccination_Communication_Guidance.pdf

EFPIA Japan
ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017, Japan
Tel: +81-3- 6417-2032
Fax: +81-3- 6685-4870

Part 1 presents dialogue examples of communication when vaccination is given in a doctor’soffice, complemented by the points intended by the conversations. Part 2 provides more detailed
explanations of Part 1, including communication about vaccine efficacy and adverse events. Inaddition, the guidance proposes how to create a favorable atmosphere by physicians in adoctor’s office and waiting room, and suggests the two-way communication necessary to relieve
the anxiety and tension that vaccinees may vaguely feel.
"Communication Guidance for Vaccination" has been developed with the cooperation of thefollowing experts.
・Satoshi Iwata (Director, Infectious disease department, National Cancer Center Hospital)
・Nobuhiko Okabe (Chief, Kawasaki City Health and Safety Research Institute)・Satoshi Kamayachi (Permanent member, Japan Medical Association)
・Mikihito Tanaka (Professor, Faculty of Political Science and Economics, WASEDA University)
・Hideaki Nagai (Director, National Hospital Organization Tokyo National Hospital)
・Kuniko Nakayama (Director, My family clinic)（In Japanese alphabetical order）
EFPIA Japan will contribute to promoting an environment where people can receive inoculations
with understanding of the significance of vaccinations by supporting the improvement ofcommunication between physicians and vaccine recipients.
About EFPIA Japan (http://efpia.jp/)
Established in April 2002, EFPIA Japan represents 21 R&D-based European pharmaceuticalcompanies operating in Japan. In 2020, combined sales from the member companies accounted
for roughly 23% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to“Contribute to healthcare and patients in Japan through the early introduction of innovative
medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in orderto improve Japanese healthcare for all.
About EFPIA (European Federation of Pharmaceutical Industries and Associations)(http://www.efpia.eu)
EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents thepharmaceutical industry operating in Europe. Through its direct membership of 36 nationalassociations and 39 leading pharmaceutical companies, EFPIA provides the voice of companies

EFPIA Japan
ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017, Japan
Tel: +81-3- 6417-2032
Fax: +81-3- 6685-4870

committed to researching, developing and bringing new medicines to improve health and qualityof life around the world.
Contact:
Yuko Kidoguchi
EFPIA Japan Messaging & Communications Committee
1-6-5 Marunouchi Chiyoda-ku, Tokyo 100-8268
Bayer Holding Ltd.
Tel: 03-6266-7757
Email: yuko.kidoguchi@bayer.com

3